title: Suppression and activation of the malignant phenotype by extracellular matrix in xenograft models of bladder cancer: a model for tumor cell "dormancy".
abstract: A major problem in cancer research is the lack of a tractable model for delayed metastasis. Herein we show that cancer cells suppressed by SISgel, a gel-forming normal ECM material derived from Small Intestine Submucosa (SIS), in flank xenografts show properties of suppression and re-activation that are very similar to normal delayed metastasis and suggest these suppressed cells can serve as a novel model for developing therapeutics to target micrometastases or suppressed cancer cells. Co-injection with SISgel suppressed the malignant phenotype of highly invasive J82 bladder cancer cells and highly metastatic JB-V bladder cancer cells in nude mouse flank xenografts. Cells could remain viable up to 120 days without forming tumors and appeared much more highly differentiated and less atypical than tumors from cells co-injected with Matrigel. In 40% of SISgel xenografts, growth resumed in the malignant phenotype after a period of suppression or dormancy for at least 30 days and was more likely with implantation of 3 million or more cells. Ordinary Type I collagen did not suppress malignant growth, and tumors developed about as well with collagen as with Matrigel. A clear signal in gene expression over different cell lines was not seen by transcriptome microarray analysis, but in contrast, Reverse Phase Protein Analysis of 250 proteins across 4 cell lines identified Integrin Linked Kinase (ILK) signaling that was functionally confirmed by an ILK inhibitor. We suggest that cancer cells suppressed on SISgel could serve as a model for dormancy and re-awakening to allow for the identification of therapeutic targets for treating micrometastases.
authors.affiliation: Department of Urology, College of Medicine, Oklahoma University Health Sciences Center, Oklahoma City, Oklahoma, United States of America. Robert-hurst@ouhsc.edu
authors.forename: Robert E
authors.initials: RE
authors.lastname: Hurst
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Hauser
authors.forename: Kimberly D
authors.initials: KD
authors.lastname: Kyker
authors.forename: Jonathan E
authors.initials: JE
authors.lastname: Heinlen
authors.forename: Jason P
authors.initials: JP
authors.lastname: Hodde
authors.forename: Michael C
authors.initials: MC
authors.lastname: Hiles
authors.forename: Stanley D
authors.initials: SD
authors.lastname: Kosanke
authors.forename: Mikhail
authors.initials: M
authors.lastname: Dozmorov
authors.forename: Michael A
authors.initials: MA
authors.lastname: Ihnat
mesh_terms: D000818:Animals; D018929:Cell Culture Techniques; D045744:Cell Line, Tumor; D016000:Cluster Analysis; D004195:Disease Models, Animal; D005109:Extracellular Matrix / Q000378:metabolism*; D015870:Gene Expression; D017930:Genes, Reporter; D064593:Heterografts; D006801:Humans; D019394:Ki-67 Antigen / Q000378:metabolism; D051379:Mice; D010641:Phenotype; D040081:Protein Array Analysis; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D015398:Signal Transduction; D047368:Tumor Burden; D001749:Urinary Bladder Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology*; D014746:Vimentin / Q000378:metabolism; D000099200:Scaffold Protein ILK
chemical_list: D019394:Ki-67 Antigen; D017346:Protein Serine-Threonine Kinases; D014746:Vimentin; D000099200:Scaffold Protein ILK